Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab biosimilar, SYN-060 |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Phase 2 | EU | 29 Aug 2022 | |
Rheumatoid Arthritis | Phase 1 | AU | 26 Sep 2017 |